432 related articles for article (PubMed ID: 23540284)
1. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
2. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Lo YL; Liu Y
PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
[TBL] [Abstract][Full Text] [Related]
3. pH-and thermo-sensitive pluronic/poly(acrylic acid) in situ hydrogels for sustained release of an anticancer drug.
Lo YL; Hsu CY; Lin HR
J Drug Target; 2013 Jan; 21(1):54-66. PubMed ID: 23009351
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
[TBL] [Abstract][Full Text] [Related]
5. The Use of a Liposomal Formulation Incorporating an Antimicrobial Peptide from Tilapia as a New Adjuvant to Epirubicin in Human Squamous Cell Carcinoma and Pluripotent Testicular Embryonic Carcinoma Cells.
Lo YL; Lee HP; Tu WC
Int J Mol Sci; 2015 Sep; 16(9):22711-34. PubMed ID: 26393585
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
Lo YL; Liu FI; Yang JM; Cherng JY
Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
[TBL] [Abstract][Full Text] [Related]
7. Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells.
Lo YL; Tu WC
Chem Biol Interact; 2015 Dec; 242():13-23. PubMed ID: 26335193
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
[TBL] [Abstract][Full Text] [Related]
9. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
10. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin.
Lo YL; Ho CT; Tsai FL
Eur J Pharm Sci; 2008 Sep; 35(1-2):52-67. PubMed ID: 18606222
[TBL] [Abstract][Full Text] [Related]
11. Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells.
Juang V; Lee HP; Lin AM; Lo YL
Int J Nanomedicine; 2016; 11():6047-6064. PubMed ID: 27895479
[TBL] [Abstract][Full Text] [Related]
12. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T
Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407
[TBL] [Abstract][Full Text] [Related]
14. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro.
Lo YL; Wang W
Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of epirubicin in thermogelling and bioadhesive liquid and solid suppository formulations for rectal administration.
Lo YL; Lin Y; Lin HR
Int J Mol Sci; 2013 Dec; 15(1):342-60. PubMed ID: 24384838
[TBL] [Abstract][Full Text] [Related]
17. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
18. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
20. A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma Caco-2 cells.
Lo YL
Int J Mol Sci; 2012 Dec; 14(1):158-76. PubMed ID: 23344026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
